The Senate hearing with Dr. Anthony Fauci reignited questions about U.S.-funded research tied to the Wuhan Institute of Virology and pushed the NIH to announce a new, risk-based policy that bans dangerous gain-of-function work and tightens oversight, enforcement, and international restrictions.
The recent grilling of Dr. Anthony Fauci by Sen. Rand Paul highlighted long-standing concerns over potential U.S. involvement in Wuhan laboratory research and whether that work contributed to the COVID-19 outbreak. The hearing brought those suspicions back into public view and underscored why tighter controls on risky life sciences research are gaining traction. Lawmakers and the public are demanding accountability and clearer boundaries on taxpayer-funded science.
Now the National Institutes of Health has unveiled a new approach, described as a government-wide, risk-based policy called the “.” The announcement frames the change as both a ban on certain dangerous research and a move toward stronger, more transparent oversight. That shift aims to prevent federally supported experiments that could significantly endanger American lives or national security.
https://x.com/NIHDirector_Jay/status/2082528139125657648
During my confirmation hearing, I pledged to the American public that I would implement strong and transparent oversight of NIH-supported research.
Now, I am pleased to share the new U.S. Government Policy for Stopping High-Risk Life Sciences Research, a groundbreaking government-wide mandate that expressly prohibits gain-of-function research which can significantly endanger American lives and jeopardize our Nation’s security.
The policy text emphasizes an explicit prohibition on dangerous gain-of-function experiments and replaces the previous, looser system with “a comprehensive, risk-based framework supported by strong enforcement, accountability, and transparency measures.” Independent, top-down assessments will be required for projects that could raise the harmful consequences of biological agents. The new rules also call for enhanced review and reporting across all life sciences work funded by the federal government.
This groundbreaking government-wide policy establishes, for the first time, an explicit prohibition on dangerous gain-of-function research which can significantly endanger American lives and pose substantial risk to our Nation’s security.
The new U.S. Government-wide policy represents a paradigm shift in federal oversight by adopting a comprehensive, risk-based framework supported by strong enforcement, accountability, and transparency measures. In addition to the ban on federal support for dangerous gain-of-function research, the policy introduces enhanced review and reporting requirements for all life sciences research, including independent, top-down assessments for projects that may increase the harmful consequences of biological agents.
The policy also strengthens global safeguards by instituting new international restrictions, including banning life sciences research involving certain countries or entities and prohibiting high-risk work in countries lacking adequate oversight.
Secretary of Health and Human Services Robert F. Kennedy Jr. also weighed in on the policy and its intent to shift federal practice away from funding risky experiments overseas. His statement stresses the government’s responsibility to protect citizens rather than underwrite work that could put them at risk. The new stance aligns with political pressure to prioritize safety and sovereignty over research partnerships in nations with questionable oversight.
The federal government has a duty to protect the American people — not fund research that could put them at risk. Today, we are ending federal support for dangerous gain-of-function research and replacing weak oversight with clear, enforceable safeguards. This policy delivers on President Trump’s commitment to put safety first while ensuring America remains the global leader in ethical, responsible, and lifesaving biomedical research.
The phrase “no more Faucis” has circulated as a blunt political shorthand for ending the era of perceived unaccountable public health power and overseas research entanglements. That sentiment reflects a larger appetite for reform: tighter rules, clearer penalties, and less reliance on foreign labs that may lack robust safety systems. Supporters want the U.S. to do necessary defensive science at home under strict conditions, not outsource risky work abroad.
Concerns about gain-of-function research are not theoretical. Critics note that certain experiments sit close to the line separating defensive science from activities that could be misused or cause accidental releases. The NIH policy tries to draw that line more clearly while maintaining the ability to support legitimate, low-risk research that advances public health.
Moving forward, the policy promises new review structures, international limits, and mechanisms to stop federally backed work that crosses into high-risk territory. Implementing those measures will test whether the federal government can both protect national security and preserve scientific progress, all while restoring public trust in how research is funded and supervised.
Public debate will continue, especially over how aggressively to pursue countermeasures and how much research the government should centralize domestically. What seems clear is that the policy marks a deliberate change in direction, seeking to prevent future missteps and prioritize safety in the lifesciences arena.
Add comment